Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments - Product Image

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • ID: 4039309
  • Report
  • Region: Global
  • 133 Pages
  • GBI Research
1 of 6
Global Neurodegenerative Drugs Market Set to Hit $45 Billion by 2022

FEATURED COMPANIES

  • AbbVie
  • Acadia
  • Biogen
  • Celgene
  • Eli Lilly
  • Lundbeck
  • MORE
Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

Market for neurodegenerative disorders, which covers Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD) and multiple sclerosis (MS) is expected to experience continuous growth over the forecast period, from $27.2 Billion in 2015 to $45 Billion in 2022, at a compound annual growth rate (CAGR) of 7.42%. Much of this growth is expected to occur between 2018 and 2022, due to the approval of many pipeline products within these years. Just under half of the global neurodegenerative disorders market belongs to the US, which accounted for $11.5 Billion in 2015.

Revenue for the highest-selling product within the multiple sclerosis (MS) market - Copaxone (glatiramer acetate), marketed by Teva - is expected to decrease substantially following its 2014 patent expiry, from $4.02 Billion in 2015 to $2.5 Billion in 2022, due to competition from generics, such as Glatopa. Declining revenues from this and other drugs - due to generic competition, as well as a lack of late-stage pipeline products - will lead to a significant drop in the neurodegenerative disorder market share for Teva. The approval of ocrelizumab within the forecast period, on the other hand, is anticipated to boost revenues for Roche, making it a key player in the market.

There is a large pharmaceutical pipeline for neurodegenerative disorders, consisting of 1,201 products in active development. Some 50 of these are in Phase III development, although the majority of pipeline products (79%) are in the early stages of development, at either the Preclinical or Discovery stages.

Small molecule drugs currently dominate the market space; 742 pipeline products (64%) are small molecules, of which ten are expected to enter the market within the forecast period. Some 26% of the pipeline is made up of biologics. The majority of the pipeline products are novel active pharmaceutical ingredients (API), with only a small proportion of products being either generics, or repositioned from other indications - the majority of which are at Phase I. This indicates progress in terms of different molecules being developed as therapeutic agents within the neurodegenerative pipeline.

The report “Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments” focuses on five key indications within neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in amyotrophic lateral sclerosis and multiple sclerosis.

In particular, it provides for the following:
  • Provides a detail glance of current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis.
  • Analysis of neurodegenerative disorders pipeline and stratify by stage of development, molecule type and molecular target, making use of a granular breakdown across key indications.
  • To understand the growth in patient epidemiology and market revenues for the neurodegenerative disorders market, globally and across the key players and product types.
  • Identifies the commercial opportunities in the neurodegenerative disorders deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie
  • Acadia
  • Biogen
  • Celgene
  • Eli Lilly
  • Lundbeck
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.1.1 Alzheimer’s Disease
2.1.2 Parkinson’s Disease
2.1.3 Huntington’s Disease
2.1.4 Amyotrophic Lateral Sclerosis
2.1.5 Multiple Sclerosis
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.3.1 Pathophysiology
2.4 Epidemiology Patterns: Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
2.4.1 Alzheimer’s Disease
2.4.2 Parkinson’s Disease
2.4.3 Huntington’s Disease
2.4.4 Amyotrophic Lateral Sclerosis
2.4.5 Multiple Sclerosis
2.5 Co-morbidities and Complications
2.6 Treatment
2.6.1 Alzheimer’s Disease
2.6.2 Parkinson’s Disease
2.6.3 Huntington’s Disease
2.6.4 Amyotrophic Lateral Sclerosis
2.6.5 Multiple Sclerosis

3 Key Marketed Products
3.1 Overview
3.2 Tecfidera (dimethyl fumarate) - Biogen
3.3 Copaxone (glatiramer acetate) - Teva
3.4 Tysabri (natalizumab) - Biogen
3.5 Gilenya (fingolimod hydrochloride) - Novartis
3.6 Avonex (interferon beta-1a) - Biogen
3.7 Plegridy (peginterferon beta-1a) - Biogen
3.8 Namenda/Memary/Ebixa/Axura/Namenda XR (memantine hydrochloride/memantine hydrochloride ER) - Merz Pharma/Lundbeck/Forest/Daiichi Sankyo
3.9 Nuplazid (pimavanserin tartrate) - Acadia

4 Pipeline Landscape Assessment
4.1 Pipeline Development Landscape
4.2 Molecular Targets in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Aggregate Clinical Program Size
4.4 Assessment of Key Pipeline Products
4.4.1 Ocrelizumab - Roche
4.4.2 Ozanimod - Celgene
4.4.3 Solanezumab - Eli Lilly
4.4.4 Crenezumab - Roche
4.4.5 Tirasemtiv - Cytokinetics
4.4.6 CVT-301 (Levodopa) - Acorda Therapeutics
4.5 5.5 Conclusion

5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Immunomodulators (interferon receptor/S1PR1/MHC II/IL-2 receptor/cells expressing B lymphocyte antigen CD20/glucocorticoid receptor)
5.3.2 Neuromodulators (acetylcholinesterase/dopamine receptor/5HTA receptor)
5.3.3 Amyloid Inhibitors (Amyloid Beta Inhibitors)
5.3.4 APP inhibitors (BACE)

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Biogen - Will the Patent Expiration of Tysabri Cause a Loss in Market Size?
6.1.2 Novartis - Gradual Decline in Revenue due to Gilenya Patent Expiration
6.1.3 Roche - Approval of Ocrelizumab to Drive Market Size
6.1.4 Sanofi - Aubagio and Lemtrada to Become Blockbuster Drugs
6.1.5 Teva - Gradual Decline in Revenue due to Patent Expiration of Products
6.1.6 Acadia - Newly Approved Nuplazid Expected to Achieve Blockbuster Status in Forecast Period
6.1.7 AbbVie - Pipeline Product Approval to Significantly Increase CAGR
6.1.8 Eli Lilly - Solanezumab to Achieve Blockbuster Status following its Approval
6.1.9 Celgene - Its First Product in Neurodegenerative Disorder Market to Reach Blockbuster Status in Forecast Period
6.1.10 Lundbeck - Approval of Idalopirdine to Offset Loss in Revenue Caused by Patent Expiration of Azilect
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Table for Licensing Deals Valued above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued above $100m

8 Appendix
8.1 References
8.2 Abbreviations
8.3 Disease List
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape

List of Tables

Table 1: Neurodegenerative Disorders Therapeutics Market, Symptoms of AD, PD, HD, ALS and MS, 2016
Table 2: Neurodegenerative Disorders Therapeutics Market, Etiology of AD, PD, HD, ALS and MS, 2016
Table 3: Neurodegenerative Disorders , Global, Epidemiology of Neurodegenerative Disorders, 2016
Table 4: Neurodegenerative Disorders Therapeutics Market, Comorbidities Associated with AD, PD, HD, ALS and MS, 2016
Table 5: Neurodegenerative Disorders Therapeutics Market, Treatment Options Available for Parkinson’s Disease, 2016
Table 6: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tecfidera, 2016
Table 7: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Copaxone, 2016
Table 8: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tysabri, 2016
Table 9: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Gilenya, 2016
Table 10: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Avonex, 2016
Table 11: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Plegridy, 2016
Table 12: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Namenda/Namenda XR, 2016
Table 13: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Nuplazid, 2016
Table 14: Neurodegenerative Disorders, Global, Annual Revenue for key Products ($bn), 2015-2022
Table 15: Neurodegenerative Disorders, Global, Revenue by Company, 2015-2022
Table 16: Neurodegenerative Disorders, Global, Licensing Deals Valued above $100m, 2006-2016
Table 17: Neurodegenerative Disorders, Global, Co-development Deals Valued above $100m, 2006-2016

List of Figures

Figure 1: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Alzheimer’s Disease (‘000), 2015-2022
Figure 2: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Parkinson’s Disease (‘000), 2015-2022
Figure 3: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Huntington’s Disease (‘000), 2015-2022
Figure 4: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Amyotrophic Lateral Sclerosis (‘000), 2015-2022
Figure 5: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Multiple Sclerosis (‘000), 2015-2022
Figure 6: Neurodegenerative Disorders, Global, Key Marketed Products and Approved Indications, 2016
Figure 7: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tecfidera ($bn), 2013-2022
Figure 8: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Copaxone ($bn), 2006-2022
Figure 9: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tysabri ($bn), 2006-2022
Figure 10: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Gilenya ($bn), 2011-2022
Figure 11: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Avonex ($bn), 2006-2022
Figure 12: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Plegridy ($bn), 2014-2022
Figure 13: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Namenda/Namenda XR ($bn), 2006-2022
Figure 14: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Nuplazid ($bn), 2016-2022
Figure 15: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Neurodegenerative Disorder by Stage of Development, Molecule Type and Program Type, 2016
Figure 16: Breakdown of Biologics in Neurodegenerative Disorders Pipeline, 2016
Figure 17: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Stage of Development, 2016
Figure 18: Neurodegenerative Disorders Therapeutics Market, Pipeline by Mechanism of Action (%), 2016
Figure 19: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Mechanism of Action, 2016
Figure 20: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 21: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 22: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 23: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 24: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 25: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 26: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 27: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 28: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
Figure 29: Neurodegenerative disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2015
Figure 30: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 31: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 32: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development (patients), 2006-2016
Figure 33: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 34: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2015
Figure 35: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 36: Neurodegenerative Disorders, Global, Annual Revenue for Ocrelizumab ($bn), 2016-2022
Figure 37: Neurodegenerative Disorders, Global, Annual Revenue for Ozanimod ($bn), 2018-2022
Figure 38: Neurodegenerative Disorders, Global, Annual Revenue for Solanezumab ($bn), 2017-2022
Figure 39: Neurodegenerative Disorders, Global, Annual Revenue for Crenezumab ($m), 2017-2022
Figure 40: Neurodegenerative Disorders, Global, Annual Revenue for Tirasemtiv ($m), 2019-2022
Figure 41: Neurodegenerative Disorders, Global, Annual Revenue for CVT-301 ($m), 2018-2022
Figure 42: Neurodegenerative Disorder Therapeutics Market, Global, Market Size ($bn), 2015-2022
Figure 43: Neurodegenerative Disorders, Global, Annual Revenue for Key Products ($m), 2014-2022
Figure 44: Neurodegenerative Disorders, Global, Annual Revenue for Immunomodulators ($bn), 2015-2022
Figure 45: Neurodegenerative Disorders, Global, Annual Revenue for Neuromodulators ($bn), 2015-2022
Figure 46: Neurodegenerative Disorders, Global, Annual Revenue for Amyloid Inhibitors ($bn), 2015-2022
Figure 47: Neurodegenerative Disorders, Global, Annual Revenue for APP inhibitors ($m), 2015-2022
Figure 48: Neurodegenerative Disorders Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 49: Neurodegenerative Disorders, Global, Market Share by Company (%), 2015-2022
Figure 50: Neurodegenerative Disorders, Global, Companies by Compound Annual Growth Rate (%), 2014-2022
Figure 51: Neurodegenerative Disorders, Global, Revenue by Product Type, 2015-2022
Figure 52: Neurodegenerative Disorders, Global, Biogen Annual Revenue ($bn), 2015-2022
Figure 53: Neurodegenerative Disorders, Global, Novartis Annual Revenue ($bn), 2015-2022
Figure 54: Neurodegenerative Disorders, Global, Roche Annual Revenue ($bn), 2015-2022
Figure 55: Neurodegenerative Disorders, Global, Sanofi Annual Revenue ($bn), 2015-2022
Figure 56: Neurodegenerative Disorders, Global, Teva Annual Revenue ($bn), 2015-2022
Figure 57: Neurodegenerative Disorders, Global, Acadia Annual Revenue ($bn), 2015-2022
Figure 58: Neurodegenerative Disorders, Global, AbbVie Annual Revenue ($m), 2015-2022
Figure 59: Neurodegenerative Disorders, Global, Eli Lilly Annual Revenue ($m), 2015-2022
Figure 60: Neurodegenerative Disorders, Global, Celgene Annual Revenue ($m), 2015-2022
Figure 61: Neurodegenerative Disorders, Global, Lundbeck Annual Revenue ($m), 2015-2022
Figure 62: Neurodegenerative Disorders, Global, Companies by Type, 2016
Figure 63: Neurodegenerative Disorders, Global, High-Activity and Late-Stage Pipeline Developers by Level of Neurodegenerative Disorders, 2016
Figure 64: Neurodegenerative Disorders, Global, Proportion of Total Company Revenue Attributed to Neurodegenerative Disorders, 2015-2022
Figure 65: Neurodegenerative Disorders, Global, Licensing Deals, 2006-2016
Figure 66: Neurodegenerative Disorders, Global, Licensing Deals by Indication and Value, 2006-2016
Figure 67: Neurodegenerative Disorders, Global, Licensing Deals, 2006-2016
Figure 68: Neurodegenerative Disorders, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
Figure 69: Neurodegenerative Disorders, Global, Co-development Deals, 2006-2016
Figure 70: Neurodegenerative Disorders, Global, Co-development Deals by Indication and Value, 2006-2016
Figure 71: Neurodegenerative Disorders, Global, Co-development Deals, 2006-2016
Figure 72: Neurodegenerative Disorders, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie
  • Acadia
  • Biogen
  • Celgene
  • Eli Lilly
  • Lundbeck
  • MORE

Global neurodegenerative drugs market set to hit $45 billion by 2022

The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%, according to the author.

The company’s latest report states that much of this growth is expected to occur between 2018 and 2022, due to the approval of many pipeline products within these years. Indeed, several late-stage products are expected to be highly commercially successful, including ocrelizumab, ozanimod, solanezumab, ITI-007 and RG-7412.

Qaisrah Khalid, Analyst, explains: "There is a large pharmaceutical pipeline for neurodegenerative disorders, consisting of approximately 1,494 products in active development. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics, or repositioned from other indications - most of which are at Phase I. This indicates progress in terms of different molecules being developed as therapeutic agents within the neurodegenerative pipeline."

The author also states that several key market players, such as Biogen, Novartis and Sanofi, are forecast to maintain their strong market shares throughout the forecast period, despite the fact that many of the impending patent expiries - especially that of Biogen’s Tysabri and Novartis’ Gilenya - will affect these companies directly.

Khalid continues: "The revenue for the highest-selling product within the MS market - Copaxone (glatiramer acetate), marketed by Teva - is expected to decrease substantially following its 2014 patent expiry, from just over $4 billion in 2015 to $2.5 billion by 2022, due to competition from generics, such as Glatopa. Declining revenues from this and other drugs will lead to a significant drop in the neurodegenerative disorder market share for Teva.

"On the other hand, the approval of ocrelizumab within the forecast period is anticipated to boost revenues for Roche, making it a major player in the market. As such, Roche is forecast to overtake the majority of currently leading companies in terms of total revenue."

Note: Product cover images may vary from those shown
5 of 6
  • AbbVie
  • Acadia
  • Biogen
  • Celgene
  • Eli Lilly
  • Lundbeck
  • Novartis
  • Roche
  • Sanofi
  • Teva
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll